Monte Rosa Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGS:GLUE Recent Insider Transactions by Companies or Individuals
Date	Value	Name	Entity	Shares	Max Price
29 Oct 24	SellUS$621,801	Versant Venture Management, LLC	Company	67,905	US$9.41
28 Oct 24	SellUS$869,240	Versant Venture Management, LLC	Company	89,990	US$9.66
20 Sep 24	SellUS$7,395,203	Versant Venture Management, LLC	Company	1,132,566	US$6.53
13 Sep 24	SellUS$3,404,791	Versant Venture Management, LLC	Company	567,213	US$6.16
05 Jul 24	SellUS$6,166	Edmund Dunn	Individual	1,610	US$3.83
03 Jun 24	SellUS$4,876	Edmund Dunn	Individual	1,207	US$4.04

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of GLUE?
Owner Type	Number of Shares	Ownership Percentage
Individual Insiders	451,521	0.699%
VC/PE Firms	13,345,220	20.7%
Hedge Funds	13,654,305	21.1%
Institutions	37,141,598	57.5%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 22.5%.

Top Shareholders

Top 25 shareholders own 99.02% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
12.5%	New Enterprise Associates, Inc.	7,692,298	US$51.3m	0%	2.62%
11.6%	T. Rowe Price Group, Inc.	7,116,637	US$47.5m	7.81%	no data
9.2%	Versant Venture Management, LLC	5,652,922	US$37.7m	-21.5%	16.37%
9.03%	FMR LLC	5,548,448	US$37.0m	8.76%	no data
8%	Baker Bros. Advisors LP	4,916,095	US$32.8m	0%	0.3%
7.15%	BVF Partners L.P.	4,393,210	US$29.3m	58.9%	1.08%
7.07%	Avoro Capital Advisors LLC	4,345,000	US$29.0m	-25%	0.38%
6.25%	BlackRock, Inc.	3,840,160	US$25.6m	32.4%	no data
5.14%	The Vanguard Group, Inc.	3,156,354	US$21.1m	24.6%	no data
3.59%	Morgan Stanley, Investment Banking and Brokerage Investments	2,205,045	US$14.7m	1,790%	no data
2.55%	Suvretta Capital Management, LLC	1,563,798	US$10.4m	-41.2%	0.37%
2.4%	Aisling Capital Management LP	1,472,331	US$9.8m	0%	2.95%
2.38%	GV Management Company, LLC	1,464,015	US$9.8m	0%	0.81%
2.29%	HBM Partners Ltd.	1,407,040	US$9.4m	0%	0.94%
1.75%	State Street Global Advisors, Inc.	1,076,430	US$7.2m	56.6%	no data
1.69%	Geode Capital Management, LLC	1,036,665	US$6.9m	-0.77%	no data
1.27%	Citadel Advisors LLC	778,386	US$5.2m	-32.8%	no data
0.81%	Marshall Wace LLP	499,492	US$3.3m	187%	no data
0.73%	Norges Bank Investment Management	445,868	US$3.0m	0%	no data
0.69%	Vestal Point Capital, LP	425,000	US$2.8m	-54.3%	0.16%
0.68%	Markus Warmuth	416,538	US$2.8m	0%	no data
0.61%	Northern Trust Global Investments	376,964	US$2.5m	5.13%	no data
0.6%	Charles Schwab Investment Management, Inc.	370,472	US$2.5m	6.92%	no data
0.53%	Parkwood LLC, Asset Management Arm	323,000	US$2.2m	-24.3%	0.24%
0.51%	Ikarian Capital, LLC	311,575	US$2.1m	-0.01%	0.65%

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/03/19 12:02
End of Day Share Price	2025/03/19 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Monte Rosa Therapeutics, Inc. is covered by 9 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Zhiqiang Shu	Berenberg
Richard J. Law	Credit Suisse
Michael Schmidt	Guggenheim Securities, LLC